Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors. Song Y, Cao J, Zhang Q, Li C, et al. Haematologica 2024;109:2165-2176.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Song Y, Cao J, Zhang Q, Li C, et al. Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors. Haematologica 2024;109:2165-2176.
PMID: 38235512